Nanjing Pharmaceutical Group Company Limited (SHA:600713)
China flag China · Delayed Price · Currency is CNY
5.16
-0.04 (-0.77%)
Aug 24, 2026, 3:00 PM CST

SHA:600713 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
2,0523,0494,5632,3722,3282,095
Trading Asset Securities
170.2215.28----
Cash & Short-Term Investments
2,2233,2644,5632,3722,3282,095
Cash Growth
-16.00%-28.45%92.39%1.87%11.13%41.32%
Accounts Receivable
21,08716,28915,09816,20919,30415,251
Other Receivables
877.1341.7897.929.7129.2822.86
Receivables
21,96416,33115,19616,23819,33415,274
Inventory
7,0986,9046,2865,7985,7874,518
Other Current Assets
1,1811,9131,7641,6051,8131,571
Total Current Assets
32,46528,41227,80826,01329,26123,458
Property, Plant & Equipment
2,0092,0041,8851,5071,5191,492
Long-Term Investments
271.31269.24283.47237.64206.45254.18
Goodwill
63.2463.2472.1772.1772.1772.17
Other Intangible Assets
200.35209.49215.68218.98245.28268.11
Long-Term Deferred Tax Assets
282.68271.27243.43222.82224.93180.78
Long-Term Deferred Charges
108.7598.2663.0743.3436.8934.24
Other Long-Term Assets
104.21103.18102.7495.5884.69126.24
Total Assets
35,50431,43030,67428,41031,65125,886

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
10,70411,09810,1769,69410,1318,064
Accrued Expenses
139.21335.81369.49363.63438.32379.33
Short-Term Debt
8,5874,7593,7604,5748,4147,036
Current Portion of Long-Term Debt
287.8195.14900.982,2231,409-
Current Portion of Leases
-82.8979.6376.0471.6878.28
Current Income Taxes Payable
236.98174.1387.691.48102.89136.01
Current Unearned Revenue
306.74333.99278.67103.57219.1274.78
Other Current Liabilities
2,1691,5421,4411,4411,4981,756
Total Current Liabilities
22,43118,52017,09418,56622,28417,525
Long-Term Debt
4,1134,1465,3392,1182,2222,628
Long-Term Leases
176.76192.07116.18119.02103.23124.4
Long-Term Unearned Revenue
266.1260.79277.62297.06293.17304.61
Long-Term Deferred Tax Liabilities
54.358.0459.0555.4154.2469.9
Total Liabilities
27,04123,17822,88621,15524,95620,652

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
1,3091,3091,3091,3101,3101,042
Additional Paid-In Capital
2,4582,4542,4662,4602,4291,380
Retained Earnings
3,5503,3752,9732,6112,2171,778
Treasury Stock
-43.71-51.33-20.9-35.9-38.58-
Comprehensive Income & Other
85.2698.5111.2489.7281.98406.6
Total Common Equity
7,3587,1856,8386,4356,0004,606
Minority Interest
1,1061,068949.87819.73695.03627.46
Shareholders' Equity
8,4638,2537,7887,2556,6955,234
Total Liabilities & Equity
35,50431,43030,67428,41031,65125,886

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
13,1659,37510,1969,11012,2199,867
Net Cash (Debt)
-10,942-6,111-5,634-6,738-9,891-7,772
Net Cash Growth
------
Net Cash Per Share
-7.29-4.17-4.32-5.19-7.89-7.46
Filing Date Shares Outstanding
1,3091,3091,3091,3101,3101,042
Total Common Shares Outstanding
1,3091,3091,3091,3101,3101,042
Working Capital
10,0349,89110,7147,4476,9785,933
Book Value Per Share
5.625.495.224.914.584.42
Tangible Book Value
7,0946,9126,5506,1445,6824,266
Tangible Book Value Per Share
5.425.285.004.694.344.10
Buildings
-1,4521,4631,1331,1661,046
Machinery
-962.26928.24890.32839.29762.13
Construction In Progress
-349.69237.27130.0880.23153.4